2 weeks Ago By ABMN Staff
Peloton Wealth Strategists grew its holdings in Eli Lilly and Company ( NYSE:LLY – Free Report ) by 13.4% in the second quarter, Holdings Channel.com reports.
The institutional investor owned 1,366 shares of the company’s stock after acquiring an additional 161 shares during the quarter. Peloton Wealth Strategists’ holdings in Eli Lilly and Company were worth $1,237,000 as of its most recent filing with the SEC. Other institutional investors and hedge funds have also made changes to their positions in the company.
Capital Planning LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter valued at about $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in Eli Lilly and Company during the first quarter worth about $6,916,000. M&G Plc purchased a new position in Eli Lilly and Company during the first quarter worth about $8,896,000.
HighPoint Advisor Group LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $9,878,000. Finally, Leo Wealth LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth about $3,355,000. 82.
53% of the stock is owned by hedge funds and other institutional investors. Insider Activity In other news, major shareholder Lilly Endowment Inc sold 52,369 shares of the firm’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $915.
18, for a total value of $47,927,061.42. Following the transaction, the insider now owns 97,247,403 shares of the company’s stock, valued at approximately $88,998,878,277.
54. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink . In the last 90 days, insiders have sold 423,559 shares of company stock valued at $393,136,808.
Company insiders own 0.13% of the company’s stock. Eli Lilly and Company Stock Performance Eli Lilly and Company ( NYSE:LLY – Get Free Report ) last posted its quarterly earnings results on Thursday, August 8th.
The company reported $3.92 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $1.
28. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.
83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.
52%. Analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.
Wall Street Analysts Forecast Growth Several research analysts recently issued reports on LLY shares. Wells Fargo & Company increased their price target on shares of Eli Lilly and Company from $875.00 to $1,000.
00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Barclays increased their price target on shares of Eli Lilly and Company from $913.00 to $1,025.
00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Bank of America increased their price target on shares of Eli Lilly and Company from $1,000.00 to $1,125.
00 and gave the stock a “buy” rating in a report on Friday, August 9th. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their target price for the stock from $725.
00 to $1,025.00 in a research report on Monday, August 12th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock.
According to data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $977.35. Check Out Our Latest Analysis on Eli Lilly and Company Eli Lilly and Company Company Profile ( Free Report ) Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.
The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Featured Stories Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company ( NYSE:LLY – Free Report ).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter ..
